Liezl Gambe

Atomo Diagnostics (ASX:AT1) has secured a purchase order worth $502,000 for its HIV self-tests, which will be supplied to an African country in March.

Vitrafy Life Sciences (ASX:VFY) has entered a 12-month exclusive collaboration and development agreement with global animal reproduction leader IMV Technologies, SA.

MyEco Group (ASX:MCO) has reported record quarterly sales for its MyEcoBag products, reaching $1.7 million in Q2 FY26—up 68% on the previous quarter and 40% on the prior corresponding period.

Microsoft Australia has signed a memorandum of understanding and framework agreement with the Australian Council of Trade Unions, marking a new benchmark for workers' rights in technology workplaces.

Lawmakers in Rhode Island have reintroduced a temporary bill aimed at exempting small bitcoin (CRYPTO:BTC) transactions from state income and capital gains taxes for the second year in a row.

Citigroup (NYSE:C) reported fourth-quarter adjusted earnings that comfortably beat Wall Street expectations, as a resurgence in investment banking and the steady performance of its "crown jewel" services unit helped the bank weather a massive charge related to its exit from Russia.

United Community Banks (NYSE:UCB) capped a historic 2025 on Wednesday, reporting record full-year revenue of $1.063 billion as the Greenville-based regional lender successfully navigated a volatile interest rate environment to deliver double-digit earnings growth.

NRx Pharmaceuticals (NASDAQ:NRXP) achieved a pivotal regulatory milestone Wednesday, announcing the submission of a massive real-world dataset to the U.S. Food and Drug Administration (FDA) to support the accelerated approval of NRX-100, its proprietary preservative-free ketamine.

Beam Global (NASDAQ:BEEM) delivered its strongest quarterly performance since late 2024 on Wednesday, signaling a successful pivot away from a reliance on U.S. government contracts that have stalled under the current administration’s shift in EV policy.

HUTCHMED (China) (NASDAQ:HCM) and partner AstraZeneca (NYSE:AZN) reached a major scientific milestone Wednesday with the publication of full Phase III SACHI trial results in The Lancet.